Bronchopulmonary dysplasia (BPD) is an important cause of respiratory illness in preterm infants that results in significant morbidity and mortality. BPD is a condition of chronic lung disease due to disruption of pulmonary development and injury in preterm infants. For extremely preterm infants, the incidence of BPD is approximately 40 percent and the incidence of BPD had not changed significantly in the past 20 years. Hence, BPD remains a significant burden for very preterm infants. In most cases, infants with BPD generally improve gradually during the first two to four months. However, infants with severe BPD may need prolonged mechanical ventilation and may develop pulmonary hypertension. General treatment measures for BPD include adequate nutrition for growth which can promote lung repair and development and can moderate fluid restriction. Respiratory care is supportive and should minimize additional injury. Pharmacologic interventions including diuretics and corticosteroids have been used in severe BPD. In the last decade, pre-clinical studies and clinical studies indicate that therapies with mesenchymal stem cells offer a new therapeutic approach for the prevention and treatment of BPD.
Despite recent advances in neonatal intensive care medicine, bronchopulmonary dysplasia (BPD) remains a major cause of mortality and long-term respiratory and neurologic morbidities in preterm infants. The etiology of BPD is multifactorial and generally involves disruption of lung development and injury due to antenatal and/or postnatal factors (e.g., prematurity, perinatal lung inflammation, growth restriction, mechanical ventilation, and oxygen toxicity). Although many pharmacological and nonpharmacological approaches have been tested for the prevention and treatment of BPD, only a few have contributed modestly in decreasing the incidence and/or severity of BPD. Postnatal corticosteroids remain controversial because of their association with adverse neurodevelopmental outcomes. Recently, many research groups have reported that mesenchymal stem cells (MSCs) transplantation may be safe and feasible for severe BPD. However, additional larger and controlled studies are needed to prove the safety and efficacy of MSCs transplantation for severe BPD.
This Research Topic aims to collect new findings on the pathogenesis, prevention, and management of BPD. We welcome submissions addressing, but are not limited to, the following topics:
• New findings for the pathogenesis and clinical features of BPD
• New findings for the prevention of BPD
• New findings for the management of BPD
• Prevention of lung injury, promotion of angiogenesis, and lung growth for very preterm infants
Original Research Articles, Systemic Review Articles, Review Articles, Brief Research Report Articles are welcomed.
Bronchopulmonary dysplasia (BPD) is an important cause of respiratory illness in preterm infants that results in significant morbidity and mortality. BPD is a condition of chronic lung disease due to disruption of pulmonary development and injury in preterm infants. For extremely preterm infants, the incidence of BPD is approximately 40 percent and the incidence of BPD had not changed significantly in the past 20 years. Hence, BPD remains a significant burden for very preterm infants. In most cases, infants with BPD generally improve gradually during the first two to four months. However, infants with severe BPD may need prolonged mechanical ventilation and may develop pulmonary hypertension. General treatment measures for BPD include adequate nutrition for growth which can promote lung repair and development and can moderate fluid restriction. Respiratory care is supportive and should minimize additional injury. Pharmacologic interventions including diuretics and corticosteroids have been used in severe BPD. In the last decade, pre-clinical studies and clinical studies indicate that therapies with mesenchymal stem cells offer a new therapeutic approach for the prevention and treatment of BPD.
Despite recent advances in neonatal intensive care medicine, bronchopulmonary dysplasia (BPD) remains a major cause of mortality and long-term respiratory and neurologic morbidities in preterm infants. The etiology of BPD is multifactorial and generally involves disruption of lung development and injury due to antenatal and/or postnatal factors (e.g., prematurity, perinatal lung inflammation, growth restriction, mechanical ventilation, and oxygen toxicity). Although many pharmacological and nonpharmacological approaches have been tested for the prevention and treatment of BPD, only a few have contributed modestly in decreasing the incidence and/or severity of BPD. Postnatal corticosteroids remain controversial because of their association with adverse neurodevelopmental outcomes. Recently, many research groups have reported that mesenchymal stem cells (MSCs) transplantation may be safe and feasible for severe BPD. However, additional larger and controlled studies are needed to prove the safety and efficacy of MSCs transplantation for severe BPD.
This Research Topic aims to collect new findings on the pathogenesis, prevention, and management of BPD. We welcome submissions addressing, but are not limited to, the following topics:
• New findings for the pathogenesis and clinical features of BPD
• New findings for the prevention of BPD
• New findings for the management of BPD
• Prevention of lung injury, promotion of angiogenesis, and lung growth for very preterm infants
Original Research Articles, Systemic Review Articles, Review Articles, Brief Research Report Articles are welcomed.